Search

Displaying results 2871 - 2880 of 7452 in total
  1. Drug

    Fusafungine

    go.drugbank.com/drugs/DB08965
    ApprovedWithdrawn

    Fusafungine is an antibiotic from Fusarium lateririum, and is used for the treatment of respiratory infections.

  2. Drug

    LetibotulinumtoxinA

    go.drugbank.com/drugs/DB16820
    Approved

    [L42335] It was approved for use in the treatment of glabellar lines in Canada in June 2022[L42330,L42335] and in the US in March 2024.[L50291,L50296] … [A249920] It was subsequently approved by the FDA in 1992 for use in aesthetic procedures and has since become one of the most popular cosmetic procedures worldwide.

  3. Drug

    Anatibant

    go.drugbank.com/drugs/DB05038
    Experimental

    It is developed for the for the treatment of traumatic brain injury (TBI).

  4. Drug

    Fexapotide

    go.drugbank.com/drugs/DB05493
    Investigational

    NX-1207 is an investigational new drug for BPH, whose chemical entity and mechanism of action remain undisclosed. … Nymox Pharmaceutical Corporation recently completed studies of NX-1207 for treatment of benign prostatic hyperplasia (BPH).

  5. Drug

    Treprostinil

    go.drugbank.com/drugs/DB00374
    ApprovedInvestigational

    Treprostinil was approved by the FDA in 2002 for the treatment of pulmonary arterial hypertension. … The first generic form of treprostinil became available in 2019.[A248775]

  6. Drug

    Taletrectinib

    go.drugbank.com/drugs/DB18711
    ApprovedInvestigational

    [A274158] As part of the second-generation of ROS1 inhibitors, taletrectinib is significantly more potent against ROS1 resistance mutations - for example, the IC50 for taletrectinib against ROS1 exhibiting … [A274118] Taletrectinib was approved by the US FDA in June 2025 for use in patients with advanced ROS1-positive NSCLC.[L53308,L53523]

  7. Drug

    Sinapultide

    go.drugbank.com/drugs/DB11332
    ApprovedWithdrawn

    [L2502] Windtree Therapeutics plans a phase III trial for Respiratory distress syndrome in 2018.

  8. Drug

    Mobocertinib

    go.drugbank.com/drugs/DB16390
    ApprovedInvestigationalWithdrawn

    [L38319] Mobocertinib, under the brand name Exkivity (Takeda Pharmaceuticals Inc.), was granted accelerated approval by the FDA in September 2021 for the treatment of locally advanced or metastatic

  9. Drug

    Yttrium Y-90

    go.drugbank.com/drugs/DB13076
    ApprovedInvestigational

    Yttrium 90 has been investigated for the treatment of Colon Cancer and Colorectal Cancer.

  10. Drug

    Folitixorin calcium

    go.drugbank.com/drugs/DB05308
    Investigational

    ANX-510 (CoFactor) is a folate-based biomodulator drug being developed to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapy, 5-fluorouracil (5-FU). CoFactor use with 5-FU is being evaluated in cli...